(ATNX) – Press Releases
-
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
-
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO
-
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update
-
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update
-
Athenex Announces a Reverse Stock Split
-
Athenex Announces a Reverse Stock Split
-
Athenex Announces MHRA Decision on Oral Paclitaxel
-
Athenex Announces MHRA Decision on Oral Paclitaxel
-
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
-
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
-
Athenex Exits 503B Sterile Compounding Business
-
Athenex Exits 503B Sterile Compounding Business
-
Athenex Announces Positive Results of Special Stockholder Meeting
-
Athenex Announces Positive Results of Special Stockholder Meeting
-
Athenex Announces Closing of the Sale of its China API Business
-
Athenex Announces Closing of the Sale of its China API Business
-
Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference
-
Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference
-
Athenex Announces Receipt of Positive Nasdaq Listing Determination
-
Athenex Announces Receipt of Positive Nasdaq Listing Determination
-
Athenex Provides Third Quarter 2022 Financial Results and Business Update
-
Athenex Provides Third Quarter 2022 Financial Results and Business Update
-
Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022
-
Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022
-
Athenex Files Definitive Proxy Statement for Special Stockholder Meeting
-
Athenex Files Definitive Proxy Statement for Special Stockholder Meeting
-
Athenex to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Athenex to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
-
Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
-
Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants
-
Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants
-
Athenex Provides Second Quarter 2022 Financial Results and Business Update
-
Athenex Provides Second Quarter 2022 Financial Results and Business Update
-
Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical On
-
Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical On
-
Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022
-
Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022
-
Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.
-
Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.
-
Athenex to Participate in Truist Securities Cell Therapy Symposium
-
Athenex to Participate in Truist Securities Cell Therapy Symposium
-
Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree
-
Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree
-
Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy
-
Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy
-
Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC)
-
Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC)
-
Athenex Provides First Quarter 2022 Financial Results and Business Update
-
Athenex Provides First Quarter 2022 Financial Results and Business Update
Back to ATNX Stock Lookup
